ID   I 2.1
AC   CVCL_3724
SY   I-2-1; I2.1; I2-1
DR   CLO; CLO_0004316
DR   ATCC; CRL-2572
DR   BioSample; SAMN03471680
DR   cancercelllines; CVCL_3724
DR   CCRID; 1101HUM-PUMC000241
DR   Cell_Model_Passport; SIDM01223
DR   LINCS_LDP; LCL-1027
DR   Wikidata; Q54897059
RX   PubMed=10616904;
CC   Population: Caucasian.
CC   Characteristics: Lacks expression of FADD (PubMed=10616904).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: ChEBI; CHEBI:132982; Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride; Acridine mutagen ICR 191).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC=CRL-2572; CCRID=1101HUM-PUMC000241
ST   Amelogenin: X (CCRID=1101HUM-PUMC000241)
ST   Amelogenin: X,Y (ATCC=CRL-2572)
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 11
ST   D18S51: 13,21
ST   D19S433: 13,15.2
ST   D21S11: 31.2,33.2
ST   D2S1338: 19,23
ST   D3S1358: 15,17
ST   D5S818: 9
ST   D7S820: 8,10
ST   D8S1179: 12,14
ST   FGA: 19,22
ST   Penta D: 11
ST   Penta E: 10,12
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 17,18
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1061 ! Jurkat clone A3
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   PubMed=10616904;
RA   Juo P., Woo M.S.-A., Kuo C.J., Signorelli P., Biemann H.-P.,
RA   Hannun Y.A., Blenis J.;
RT   "FADD is required for multiple signaling events downstream of the
RT   receptor Fas.";
RL   Cell Growth Differ. 10:797-804(1999).
//